Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Paulus

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Studies in Health Technology and Informatics|February 24, 2001
Can factors influencing in-patient treatment in Hodgkin's disease be identified?--Retrospective analysis of HD6 patients of the GHSGB Pfistner, U Paulus, J P Glossmann, et al.
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|January 1, 1996
Influence of altered gravity on the cytochemical localization of cytochrome oxidase activity in central and peripheral gravisensory systems in developing cichlid fishU Paulus, G Nindl, K H Körtje, et al.
European Journal of Cancer Care|September 14, 2006
Cost of illness of malignant lymphoma in GermanyA Reis, P Ihle, U Paulus, et al.
The American Journal of Pathology|November 5, 1997
Classical Hodgkin's disease. Clinical impact of the immunophenotypeR von Wasielewski, M Mengel, R Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study GroupM Sieber, H Bredenfeld, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study GroupV Diehl, J Franklin, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study GroupV Diehl, J Franklin, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy aloneE Dühmke, J Franklin, M Pfreundschuh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trialM Sieber, H Tesch, B Pfistner, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Studies in Health Technology and Informatics|February 24, 2001
Can factors influencing in-patient treatment in Hodgkin's disease be identified?--Retrospective analysis of HD6 patients of the GHSGB Pfistner, U Paulus, J P Glossmann, et al.
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|January 1, 1996
Influence of altered gravity on the cytochemical localization of cytochrome oxidase activity in central and peripheral gravisensory systems in developing cichlid fishU Paulus, G Nindl, K H Körtje, et al.
European Journal of Cancer Care|September 14, 2006
Cost of illness of malignant lymphoma in GermanyA Reis, P Ihle, U Paulus, et al.
The American Journal of Pathology|November 5, 1997
Classical Hodgkin's disease. Clinical impact of the immunophenotypeR von Wasielewski, M Mengel, R Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study GroupM Sieber, H Bredenfeld, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study GroupV Diehl, J Franklin, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study GroupV Diehl, J Franklin, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy aloneE Dühmke, J Franklin, M Pfreundschuh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trialM Sieber, H Tesch, B Pfistner, et al.
Pageof 3